RxDoctor Payments Data

Susan Lee, MD

Family Medicine · Laguna Niguel, CANPI 1992975957

Payments from drug & device makers

$740in general payments, 2019–2025

Across 28 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$291
  • Exact Sciences$76
  • Novo Nordisk$76
  • GSK$70
  • Pfizer$42
  • Edwards Lifesciences$38
  • plus $146 from 6 others

What the payments were for

  • Consulting fees$253%
  • Food & beverage$71597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$740 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$50,434
Medicare patients
206
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban13$22,382
OzempicSemaglutide13$22,028
JanuviaSitagliptin Phosphate14$17,537
BrilintaTicagrelor11$13,393
MounjaroTirzepatide11$12,520
Breo ElliptaFluticasone/Vilanterol12$6,448
PremarinEstrogens, Conjugated13$6,148
CreonLipase/Protease/Amylase11$5,851
Atorvastatin Calcium331$3,399
Levothyroxine Sodium235$2,728
SynthroidLevothyroxine Sodium34$2,528
Losartan Potassium204$2,506
Wixela InhubFluticasone Propion/Salmeterol23$2,274
Armour ThyroidThyroid,pork16$1,725
Rosuvastatin Calcium85$1,687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$76$22,02813 claims
AstraZenecaBrilinta$291$13,39311 claims
GSKBreo Ellipta$70$6,44812 claims
PfizerPremarin$42$6,14813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Laguna Niguel

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →